Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Erlotinib in non-small cell lung cancer treatment: current status and future development Gridelli C; Bareschino MA; Schettino C; Rossi A; Maione P; Ciardiello FOncologist 2007[Jul]; 12 (7): 840-9Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality worldwide. Standard treatment approaches such as chemotherapy, radiotherapy, and surgery have reached a plateau in this disease. Therefore, alternatives to conventional treatment, such as new molecular-targeted therapies, are needed. Targeting the epidermal growth factor receptor (EGFR) has played a central role in advancing NSCLC research, treatment, and patient outcome over the last several years. There are two EGFR tyrosine kinase inhibitors approved for the treatment of advanced NSCLC: gefitinib and erlotinib. Of these, erlotinib has shown a significant improvement in median survival, quality of life, and related symptoms in an unselected population of advanced and metastatic NSCLC patients in the second- or third-line setting. Furthermore, erlotinib has significant antitumor activity in first-line treatment. Moreover, factors that predict the efficacy of erlotinib, including clinical, pathologic, and molecular features, have been investigated. A series of studies is planned to contribute to our understanding of the role of erlotinib in NSCLC treatment. Major areas of clinical research are the assessment of erlotinib: in adjuvant treatment, combined with chemotherapy and/or radiotherapy in locally advanced disease, in the first-line therapy of advanced disease, and in combination and/or sequence with cytotoxic treatments and/or other molecular target agents.|*Antineoplastic Combined Chemotherapy Protocols[MESH]|Carcinoma, Non-Small-Cell Lung/*drug therapy/epidemiology/genetics[MESH]|Clinical Trials, Phase II as Topic[MESH]|Clinical Trials, Phase III as Topic[MESH]|ErbB Receptors/antagonists & inhibitors/genetics[MESH]|Erlotinib Hydrochloride[MESH]|Female[MESH]|Genes, erbB-1/drug effects[MESH]|Humans[MESH]|Lung Neoplasms/*drug therapy/epidemiology/genetics[MESH]|Male[MESH]|Protein Kinase Inhibitors/*administration & dosage[MESH]|Quinazolines/*administration & dosage[MESH]|Risk Factors[MESH]|Survival Analysis[MESH]|Treatment Outcome[MESH] |